Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Achim Rothe

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Oncology Reports|January 8, 2013
The properties of human CD40-activated B cells as antigen-presenting cells are not affected by PGE2Alexander Shimabukuro-Vornhagen, Andreas Draube, Tanja Liebig, et al.
Journal of Medical Case Reports|June 1, 2011
Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case reportAlexander Shimabukuro-Vornhagen, Achim Rothe, Lucia Nogova, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2004
Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell linesFriederike Heuck, Julia Ellermann, Peter Borchmann, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 18, 2012
The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cellsAlexander Shimabukuro-Vornhagen, Andreas Draube, Tanja M Liebig, et al.
Blood|May 10, 2005
The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosisBoris Böll, Hinrich Hansen, Friederike Heuck, et al.
Biological Chemistry|January 30, 2008
Ribosome display and selection of human anti-cD22 scFvs derived from an acute lymphocytic leukemia patientAchim Rothe, Anne Nathanielsz, Frank Oberhäuser, et al.
European Journal of Haematology|December 20, 2019
Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: A retrospective analysisAchim Rothe, Annika Claßen, Jonathan Carney, et al.
Journal of Biotechnology|July 3, 2007
Selection of human anti-CD28 scFvs from a T-NHL related scFv library using ribosome displayAchim Rothe, Anne Nathanielsz, Ralf J Hosse, et al.
International Journal of Molecular Medicine|March 13, 2003
A novel approach for immunization, screening and characterization of selected scFv libraries using membrane fractions of tumor cellsMehmet Kemal Tur, Achim Rothe, Michael Huhn, et al.
Oncology Research and Treatment|February 16, 2026
Vulnerability to infections and secondary immunodeficiencies in patients with non-Hodgkin's lymphomas starting anti-CD20 antibody containing therapiesRudolf Weide, Johannes Mohm, Michael Gärtner, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Oncology Reports|January 8, 2013
The properties of human CD40-activated B cells as antigen-presenting cells are not affected by PGE2Alexander Shimabukuro-Vornhagen, Andreas Draube, Tanja Liebig, et al.
Journal of Medical Case Reports|June 1, 2011
Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case reportAlexander Shimabukuro-Vornhagen, Achim Rothe, Lucia Nogova, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2004
Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell linesFriederike Heuck, Julia Ellermann, Peter Borchmann, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 18, 2012
The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cellsAlexander Shimabukuro-Vornhagen, Andreas Draube, Tanja M Liebig, et al.
Blood|May 10, 2005
The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosisBoris Böll, Hinrich Hansen, Friederike Heuck, et al.
Biological Chemistry|January 30, 2008
Ribosome display and selection of human anti-cD22 scFvs derived from an acute lymphocytic leukemia patientAchim Rothe, Anne Nathanielsz, Frank Oberhäuser, et al.
European Journal of Haematology|December 20, 2019
Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: A retrospective analysisAchim Rothe, Annika Claßen, Jonathan Carney, et al.
Journal of Biotechnology|July 3, 2007
Selection of human anti-CD28 scFvs from a T-NHL related scFv library using ribosome displayAchim Rothe, Anne Nathanielsz, Ralf J Hosse, et al.
International Journal of Molecular Medicine|March 13, 2003
A novel approach for immunization, screening and characterization of selected scFv libraries using membrane fractions of tumor cellsMehmet Kemal Tur, Achim Rothe, Michael Huhn, et al.
Oncology Research and Treatment|February 16, 2026
Vulnerability to infections and secondary immunodeficiencies in patients with non-Hodgkin's lymphomas starting anti-CD20 antibody containing therapiesRudolf Weide, Johannes Mohm, Michael Gärtner, et al.
Pageof 4